Abatacept
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Abatacept: From Rheumatoid Arthritis to Rheumatoid Vasculitis
One-Sentence Summary
Abatacept is a CTLA-4-Ig fusion protein marketed in the US as ORENCIA and used in rheumatoid arthritis. The TxGNN model predicts it may be effective for Rheumatoid Vasculitis. The supporting evidence is thin: 1 registered trial (which does not test abatacept for this condition) and 20 publications, mostly case reports and reviews. One case report describes vasculitis appearing during abatacept therapy.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Approved indication text is not provided in the source data. The literature places abatacept in rheumatoid arthritis. |
| Predicted New Indication | Rheumatoid vasculitis |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L4 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 4 license entries, all under BLA125118 (a biologic license, not an NDA) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data from DrugBank is not available. Based on known information, abatacept is a CTLA-4-Ig fusion protein that blocks CD28-mediated T-cell co-stimulation. Rheumatoid vasculitis is a serious extra-articular complication of rheumatoid arthritis and is plausibly T-cell-driven vascular inflammation, so the mechanism could be relevant.
The clinical picture is inconsistent, though. Two case reports describe rheumatoid vasculitis responding to abatacept, including a patient who had failed methotrexate, TNF inhibitors and steroids. Other reports describe new-onset vasculitis or orbital vasculitis appearing while patients were on abatacept.
The high TxGNN score is not backed by controlled data. It should be read as a hypothesis to test, not as evidence of efficacy.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT07138898 | Phase 2 | Not yet recruiting | 80 | Perioperative immunosuppressant management in rheumatology patients undergoing shoulder arthroplasty. It does not test abatacept for vasculitis. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22124545 | 2012 | Case report | Mod Rheumatol | Rheumatoid vasculitis that failed methotrexate, TNF inhibitors, steroids, plasmapheresis and an IL-6 inhibitor improved rapidly on abatacept. |
| 29930884 | 2018 | Case report | Cureus | Abatacept proposed as an option for rheumatoid vasculitis in a patient with rheumatoid arthritis and common variable immunodeficiency, where rituximab was a concern. |
| 27052429 | 2016 | Case report | Joint Bone Spine | New-onset rheumatoid vasculitis during abatacept therapy, improving after rituximab. This is the opposite direction of effect. |
| 30119075 | 2018 | Case report | Ophthalmic Plast Reconstr Surg | Orbital vasculitis in a rheumatoid arthritis patient on abatacept, progressing despite cyclophosphamide. |
| 36418100 | 2023 | Case report | Intern Med | ANCA-associated nephritis arose during abatacept plus adalimumab therapy for rheumatoid arthritis and was attenuated by tocilizumab. |
| 24854356 | 2014 | Cohort | Ann Rheum Dis | Single-centre cohort testing whether routine ANA testing predicts biologic-induced lupus and vasculitis in rheumatoid arthritis. |
| 34068884 | 2021 | Review | J Clin Med | Treatment perspectives for rheumatoid arthritis-associated episcleritis and scleritis. Indirect. |
| 31174819 | 2018 | Review | Best Pract Res Clin Rheumatol | Central nervous system involvement in rheumatoid arthritis, including cerebral vasculitis, and implications of biologic use. Indirect. |
| 33595833 | 2021 | Systematic review | BioDrugs | Immune-mediated glomerular disorders induced by biologics and targeted synthetic drugs in rheumatic diseases. Safety context. |
| 24493331 | 2015 | Case-based review | Clin Rheumatol | Abatacept in myositis. Indirect, a different disease. |
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| BLA125118 | ORENCIA | Injection, solution | Not provided in source data |
| BLA125118 | ORENCIA | Injection, solution | Not provided in source data |
| BLA125118 | ORENCIA | Injection, powder, lyophilized, for solution | Not provided in source data |
| BLA125118 | ORENCIA | Injection, solution | Not provided in source data |
Manufacturer for all entries: E.R. Squibb & Sons, L.L.C. Route: injectable.
Safety Considerations
Please refer to the package insert for safety information.
The literature above also contains case reports of vasculitis, ANCA-associated nephritis and immune-mediated glomerular disorders arising during abatacept therapy. These are relevant to any use in vasculitis.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for this indication is limited to case reports with conflicting directions of effect, and the only registered trial does not test abatacept for vasculitis. The mechanism is plausible, but it is unproven here.
To proceed, the following is needed:
- Registry or controlled data on abatacept in rheumatoid vasculitis, including how often vasculitis occurs on abatacept versus how often it responds
- The current US label text and the full package insert warnings and contraindications
- DrugBank mechanism-of-action data
- A safety review of paradoxical vasculitis and glomerular events
Other predictions in this pack:
- Polyarticular juvenile rheumatoid arthritis: L1 and S3, Proceed with Guardrails. This appears to be established use, so it confirms existing use and is not a novel repurposing candidate.
- Ankylosing spondylitis: L3, Research Question. The only direct trial is a small open-label pilot (n=30), and one 2016 review states abatacept is not effective in axial spondyloarthritis.
- Inflammatory spondylopathy: L3, Research Question.
- Vertebral disease: L4, Hold.
- Spondyloarthropathy, susceptibility to: L4, Hold.
- Hypermobility of coccyx, Kummell disease, brachydactyly-syndactyly syndrome and colobomatous microphthalmia-rhizomelic dysplasia syndrome: L5, Hold. No trials or literature were found, and no plausible mechanism is evident.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.